Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07463703 · ClinicalTrials.gov registry record · NA
Accelerated Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder
A NA study, sponsored by Cognitive FX.
- Not yet
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT07463703: Clinical Trial NA study, sponsored by Cognitive FX.
NCT07463703 is a NA study that has not yet begun recruiting, run by Cognitive FX. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07463703, a NA study, has not yet begun recruiting, sponsored by Cognitive FX.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study tests a new brain stimulation treatment for post-traumatic stress disorder (PTSD), a condition that affects millions after trauma, causing symptoms like flashbacks, avoidance, mood changes, and heightened alertness. The investigators will enroll 15 adults (ages 18-65) with PTSD. First, participants get a brain scan (fMRI) to map their unique brain connections between areas involved in fear and control-the right amygdala (fear center) and right dorsolateral prefrontal cortex (control area). Using this personalized map, the investigators will apply accelerated transcranial magnetic stimulation (TMS), a safe, non-invasive method using magnetic pulses to adjust brain activity. Treatment lasts 5 days (10 short sessions daily, totaling 90,000 pulses) targeting the identified spot to strengthen control over fear responses. The study checks if this approach is practical, safe (tracking side effects like headaches), and shows early signs of reducing PTSD symptoms (measured by questionnaires and interviews). Follow-up lasts 3 months, with repeat scans to see brain changes. This study will see if personalized, fast-paced TMS targeting the disrupted fear-control brain circuit in PTSD can be feasible and safe, and preliminarily reduce symptoms by improving brain connectivity, potentially offering a quicker alternative to standard treatments.
Primary Outcome
A change in PTSD severity will be measured via administration of the PDSD Checklist for DSM-5 (PCL-5). This is a 20-question Likert scale, with scores ranging from 0 to 80. Higher scores indicate stronger PTSD symptoms.
Interventions
- DEVICE Accelerated functional-connectivity guided transcranial magnetic stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-01 |
| Phase | NA |
What is known before NCT07463703 opens enrollment
NCT07463703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Accelerated functional-connectivity guided transcranial magnetic stimulation is the first listed.
NCT07463703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07463703 about?
NCT07463703 is a clinical study titled "Accelerated Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder". This study tests a new brain stimulation treatment for post-traumatic stress disorder (PTSD), a condition that affects millions after trauma, causing symptoms like flashbacks, avoidance, mood changes, and heightened alertness. The investigators will enroll 15 adults (ages 18-65) with PTSD. First, p...
What is the current status of trial NCT07463703?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2026-04. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07463703?
The interventions under investigation include: Accelerated functional-connectivity guided transcranial magnetic stimulation (DEVICE).
Who is sponsoring clinical trial NCT07463703?
This trial is sponsored by Cognitive FX, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07463703's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia